2026 Seoul Bio Hub–Samsung Bioepis Open Innovation Program

About

An open innovation program designed to support early-stage bio and medical startups through regular mentorship, proof-of-concept validation, and customized acceleration support at the Seoul Bio Hub. Selected companies will engage in a structured program lasting approximately one year, culminating in a final assessment to explore potential collaborations with Samsung Bioepis.

Benefits

• 🤝Regular Meetings
  Access to regular meetings with Samsung Bioepis for guidance and support.
• ✅Proof-of-Concept Validation
  Opportunity for technology validation through proof-of-concept assessments.
• 🏢Customized Acceleration
  Tailored acceleration and support for residency and rent at Seoul Bio Hub.

Eligibility Criteria

• Bio and medical companies established for less than eight years as of the announcement date
• Up to two companies will be selected
• Focus on antibody-based therapeutics, peptide-based therapeutic technologies, and AI-driven new drug development platforms

Participation Commitments

• Must participate in a step-by-step program for approximately one year
• Final assessment upon completion to consider follow-up collaborations such as joint research, technology transfer, joint commercialization, and strategic investment.

Target Sector

Bio Health

Target Location

South Korea